NCT01030640

Study To Assess Changes In The Number Of Nerves In The Skin At The Site Where Where Tanezumab Is Injected

A Phase 1, Randomized, Double- Blind (Sponsor-Open), Placebo-Controlled Study To Examine The Density Of Intraepidermal Nerve Fibers After A Single Subcutaneous Administration Of Tanezumab In Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

Subcutaneous administration of tanezumab can result in changes in the number of nerves around the injection site in the thigh.

Conditions

• Osteoarthritis Pain
• Chronic Low Back Pain
• Pain Due to Interstitial Cystitis

Interventions

Type	Name	Description
OTHER	placebo	single dose of the drug formulation
BIOLOGICAL	tanezumab	single dose of the active drug tanezumab at a dose level of 20 mg

Timeline

• Start date: 2009-12-01
• Primary completion: 2010-09-01
• Completion: 2010-09-01
• First posted: 2009-12-11
• Last updated: 2011-04-26

Locations

2 sites across 1 country: United States